<p>Cassava Sciences（SAVA -2.61%）的股票在週一上午 11:05 時下跌了 5.3%，此前在早盤時曾下跌了高達 19%。這一下跌是在上週五對 Cassava 前顧問王浩炎（Hoau-Yan Wang）提起聯邦訴訟之後發生的。</p>
<p>王被指控涉嫌與提交給美國國家衞生研究院（NIH）用於 Cassava 實驗藥物 simufilam 的資助申請有關的欺詐行為。這些資助導致 NIH 在 2017 年至 2021 年間向王和 Cassava 發放了約 1600 萬美元的獎勵。</p>
<h2>這對 Cassava Sciences 意味着什麼？</h2>
<p>Cassava 透露一些政府機構已要求提供信息和文件。公司配合了這些調查。目前 Cassava 尚未被指控任何不當行為，儘管生物科技公司在最近的 10-K 申報中承認，“我們無法預測這些正在進行的事務的結果或影響，包括政府機構是否會對我們或他人採取執法行動。”</p>
<p>在關於王被起訴的公開聲明中，Cassava 沒有透露是否與政府機構有進一步聯繫。然而，公司在聲明中強調，王和他之前工作過的醫學院 “並未參與公司的 simufilam 第三階段臨牀試驗。”</p>
<h2>Cassava Sciences 股票是一個壞消息的買點嗎？</h2>
<p>我認為投資者最好在觀望 Cassava Sciences 方面。即使不考慮王最近被起訴所帶來的不確定性，仍有許多其他生物科技股票提供更好的風險回報比。</p>

SAVA

<p>股份草莓科學（SAVA -2.61%）下跌了 5.3%，原因是前顧問王浩言因與撥款申請相關的欺詐行為被起訴。該公司正在配合政府調查，但結果和影響尚不確定。鑑於生物科技領域存在不確定性和更好的選擇，投資者被建議保持觀望態度</p>

<p>Shares of <strong>Cassava Sciences</strong>(SAVA -2.61%) were 5.3% lower as of 11:05 a.m. ET on Monday after falling as much as 19% earlier in the morning. The decline came on the heels of the federal indictment on Friday of Hoau-Yan Wang, a former consultant to Cassava.</p>
<div class="lb-trans"><p>Cassava Sciences（SAVA -2.61%）的股票在週一上午 11:05 時下跌了 5.3%，此前在早盤時曾下跌了高達 19%。這一下跌是在上週五對 Cassava 前顧問王浩炎（Hoau-Yan Wang）提起聯邦訴訟之後發生的。</p>
</div><p>Wang was accused of fraud related to grant applications made to the U.S. National Institutes of Health (NIH) for work on Cassava's experimental drug simufilam. These grants led to awards of roughly $16 million from the NIH between 2017 and 2021 to Wang and Cassava.</p>
<div class="lb-trans"><p>王被指控涉嫌與提交給美國國家衞生研究院（NIH）用於 Cassava 實驗藥物 simufilam 的資助申請有關的欺詐行為。這些資助導致 NIH 在 2017 年至 2021 年間向王和 Cassava 發放了約 1600 萬美元的獎勵。</p>
</div><h2>What does this mean for Cassava Sciences?</h2>
<div class="lb-trans"><h2>這對 Cassava Sciences 意味着什麼？</h2>
</div><p>Cassava has revealed that some government agencies have asked for information and documents. The company cooperated with these inquiries. Cassava has not been charged with any misconduct at this point, although the biotech acknowledged in its more recent 10-K filing, &#34;We cannot predict the outcome or impact of these ongoing matters, including whether a government agency may pursue an enforcement action against us or others.&#34;</p>
<div class="lb-trans"><p>Cassava 透露一些政府機構已要求提供信息和文件。公司配合了這些調查。目前 Cassava 尚未被指控任何不當行為，儘管生物科技公司在最近的 10-K 申報中承認，“我們無法預測這些正在進行的事務的結果或影響，包括政府機構是否會對我們或他人採取執法行動。”</p>
</div><p>In a public statement about Wang's indictment, Cassava didn't disclose if there had been further contact with government agencies. However, the company emphasized in this statement that Wang and the medical school where he previously worked &#34;have had no involvement in the Company's Phase 3 clinical trials of simufilam.&#34;</p>
<div class="lb-trans"><p>在關於王被起訴的公開聲明中，Cassava 沒有透露是否與政府機構有進一步聯繫。然而，公司在聲明中強調，王和他之前工作過的醫學院 “並未參與公司的 simufilam 第三階段臨牀試驗。”</p>
</div><h2>Is Cassava Sciences stock a bad-news buy?</h2>
<div class="lb-trans"><h2>Cassava Sciences 股票是一個壞消息的買點嗎？</h2>
</div><p>I think investors are better off remaining on the sidelines with regard to Cassava Sciences. Even without the uncertainty associated with Wang's recent indictment, there are plenty of other biotech stocks that offer better risk-reward propositions.</p>
<div class="lb-trans"><p>我認為投資者最好在觀望 Cassava Sciences 方面。即使不考慮王最近被起訴所帶來的不確定性，仍有許多其他生物科技股票提供更好的風險回報比。</p>
</div>

為什麼 Cassava Sciences 的股票今天下跌